Sepracor - Scientific Abstracts : BROVANA® (arformoterol)

1. Agrawal DK, Cheng G, Kelbe PW. Comparative effects of the enantiomers of formoterol on importins in human bronchial smooth muscle cells. Am J Respir Crit Care Med 2009;179:A5719 (Abstract)

2. Celli BR, Cote CG, Goodwin E, Sciarappa K, Curry L, Hanrahan JP. Change in BODE with laba therapy in COPD: Association with exacerbation frequency and patient status. Am J Respir Crit Care Med 2009;179:A6189 (Abstract)

3. Goncharova EA, Khavin IS, Goncharov DA, Krymskaya VP. Effects of formoterol isomers on mitogen-induced proliferation of human pulmonary arterial vascular smooth muscle (VSM) cells. Am J Respir Crit Care Med 2009;179:A1857 (Abstract)

4. Gross CA, Green RM, Weinberger AR, Bowler RP, Chu HW. (R )-albuterol and (R,R)-formoterol promote airway epithelial defense against bacterial infection. Am J Respir Crit Care Med 2009;179:A4974 (Abstract)

5. Krystka K, Ducka B, Robinson M, Druzhinina T, Haczku A. The long acting beta2-adrenergic receptor agonist, (R,R)-formoterol (RF), upregulates surfactant protein D (SP-D) gene and protein expression and inhibits airway inflammation induced by aspergillus fumigatus (Af) exposure. Am J Respir Crit Care Med 2009;179:A3173 (Abstract)

6. Panettieri R, Walsh J, Sims M, Kerwin E, Fogarty C, Noonan M, MacIntyre N, Claus R, Andrews WT. Comparison of efficacy and safety of arformoterol 15 μg twice daily with arformoterol 30 μg once daily in patients with COPD. Am J Respir Crit Care Med 2009;179:A4542 (Abstract)

7. Syed RZ, Krytska K, Robinson M, Ducka B, Monks R, Druzhinina T, Birnbaum MJ, Haczku A. AKT1 in involved in beta2-adrenergic receptor agonist, (R,R)-formoterol (RF) induced up-regulation of surfactant protein D (SP-D) gene and protein expression. Am J Respir Crit Care Med 2009;179:A2821 (Abstract)

8. Waterman JT, Adler KB. Differential effects of albuterol and formoterol isomers on NF-κβ activation in human airway epithelial cells. Am J Respir Crit Care Med 2009;179:A2826 (Abstract)

9. Wei S, Song W, Doran S, Estell K, Schwiebert LM, Matalon S. Mitigation of chlorine induced lung injury by Brovana. Am J Respir Crit Care Med 2009;179:A5656 (Abstract)

2008 BROVANA (arformoterol) Abstracts

1. Jung SY, Ma Z, Oh CK. Effect of formoterol stereoisomers on mast cell-dependent airway inflammation. JACI 2008;121(2):S112 (Abstract)

2. Bauer A, McGlynn P, Bovet L, Curry L, Hanrahan J. In vitro comparison of two nebulizer/compressor systems on the emitted dose of nebulized racemic formoterol and arformoterol.

3. Hanania N, Donohue J, Nelson H, Sciarappa K, Goodwin E, Baumgartner R, Hanrahan J. Long-term safety and efficacy of nebulized arformoterol in subjects with COPD. Chest 2008;134(4):106001 (Abstract)

4. Sciurba F, Cote C, Sciarappa K, Goodwin E, Curry L, Hanrahan J. Assessment of patient symptom and functioning outcomes among COPD subjects treated with arformoterol or racemic formoterol: A 6-month clinical trial. Chest 2008;134(4):16002 (Abstract)

5. Tashkin D, Donohue J, Mahler D, Huang H, Schaefer K, Hanrahan J, Andrews W. Effect of arformoterol twice daily, tiotropium once daily, and their combination in subjects with COPD. Chest 2008;134(4):104003 (Abstract)

6. Celli BR, Cote CG, Claus R, Goodwin E, Hanrahan JP. The association of BODE index and risk of exacerbations, serious respiratory adverse events, and hospitalizations in COPD patients. AJRCCM 2008;177(Supplement):A286 (Abstract)

7. Delmotte P, Sanderson MJ. Effects of enantiomers of formoterol on the contraction and ca2+ signaling of smooth muscle cells of small airways in mouse lung slices. AJRCCM 2008;177(Supplement):A486 (Abstract)

8. Bauer A, McGlynn P, Bovet L, Mims P. Aerosol properties of arformoterol tartrate inhalation solution in five nebulizer/compressor systems. Presented as a poster presentation at Southwest Allergy Forum, January 16 - 20, 208 in Puerta Vallarta, Mexico (Abstract)

9. Bauer A, McGlynn P, Bovet L, Mims P, Curry L, Hanrahan JP. The influence of breathing pattern during nebulization on the emitted dose of arformoterol. Presented as a poster presentation at Southwest Allergy Forum, January 16 - 20, 208 in Puerta Vallarta, Mexico (Abstract)

10. Bauer A, McGlynn P, Bovet L, Mims P. Aerosol properties of arformoterol tartrate inhalation solution in five nebulizer/compressor systems. Presented as poster #20 at Western Society of Asthma, Allergy & Immunology, January 21 - 25, 2008 in Kailua-Kona, HI (Abstract)

11. Bauer A, McGlynn P, Bovet L, Mims P, Curry L, Hanrahan JP. The influence of breathing pattern during nebulization on the emitted dose of arformoterol. Presented as poster #21 at Western Society of Asthma, Allergy & Immunology, January 21 - 25, 2008 in Kailua-Kona, HI (Abstract)

12. Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance. Therapeutic Advances in Respiratory Disease 2008;2(2):37-48.

13. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: Results from two randomized trials. COPD: Journal of Chronic Obstructive Pulmonary Disease 2008;5(1):25-34.

14. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum P, Morganroth J. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine 2008;87(6):319-328.

15. Kharidia J, Fogarty CM, LaForce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21:657-662.

2007 BROVANA (arformoterol) Abstracts

1. Kharidia J, Maier G, Hsu R, Hanrahan JP, Nguyen LQ, Abolin C, Dunnington KM. An evaluation of the impact of cytochrome P450 (CYP) 2D6 and UGT1A1 metabolism on the pharmacokinetics of arformoterol tartrate inhalation solution. AAPS Journal 2007;9(S2):W4479 [Abstract]

2. Bauer A, McGlynn P, Bovet LL, Mims P, Hanrahan JPH. Aerosol properties of arformoterol inhalation solution in five nebulizer/compressor systems. 53rd Annual Convention & Exhibition of the American Association for Respiratory Care Program, December 1 - 4, 2007; Orlando, FL, pp. 113 [Abstract]

3. Kharidia J, Fogarty CM, LaForce CF, Maier G, Hsu R, Dunnington KM, Curry L, Hanrahan JP. Pharmacokinetics of (R,R)- and (S,S)-formoterol following multiple doses of arformoterol inhalation solution and racemic dry powder inhaler in subjects with COPD. 53rd Annual Convention & Exhibition of the American Association for Respiratory Care Program, December 1 - 4, 2007; Orlando, FL, pp. 127 [Abstract]

4. Bauer A, McGlynn P, Bovet L, Mims P, Curry L, Hanrahan JP. The influence of breathing pattern during nebulization on the emitted dose of arformoterol. Chest 2007; 132(4):616S [Abstract]

5. Cote CG, Celli B, Sciarappa K, Baumgartner R, Hanrahan JP. Baseline BODE correlates with BDI and baseline SGRQ, but not with changes in these measures following LABA treatment in two 12-week double-blind trials. Chest 2007;132(4):521S [Abstract]

6. Hanrahan JP, Grogan D, Morganroth J, Cheng H, Baumgartner RA. The effect of twice-daily nebulized arformoterol on QTc in subjects with COPD. Chest 2007;132(4):532S [Abstract]

7. Kharidia J, Fogarty C, LaForce C, Maier G, Hsu R, Dunnington S, Curry L, Baumgartner RA, Hanrahan JP. An open label study of arformoterol inhalation solution and racemic formoterol dry powder inhaler in subjects with COPD. Chest 2007;132(4):533S [Abstract]

8. Donohue JF, Hanania NA, Sciarappa K, Grogan DR, Baumgartner RA, Hanrahan JP. Effect of nebulized arformoterol and salmeterol on short-acting bronchodilator use among subjects with COPD in a 52-week trial. JMCP 2007;13(8):697 [Abstract]

9. Kharidia J, Hsu R, Dunnington KM, Hanrahan JPH, Maier G. Pharmacokinetics of nebulized arformoterol in subjects with hepatic dysfunction. The Consultant Pharmacist 2007 (Suppl B):18 [Abstract]

10. Maier G, Hsu R, Kharidia J, Dunnington KM. Pharmacokinetics of arformoterol tartrate inhalation solution in subjects with renal impairment. International Pharmaceutical Abstracts 2007;64:9e [Abstract]

11. Maier G, Hsu R, Kharidia J, Dunnington KM. Pharmacokinetic interaction of arformoterol and paroxetine in healthy subjects. International Pharmaceutical Abstracts 2007;64:8e [Abstract]

12. Donohue JF, Hanrahan JP, Hanania N, Sciarappa K, Baumgartner RA. Long-term safety of 50-μg once-daily nebulized arformoterol in COPD: a 12-month trial. American Journal of Respiratory and Critical Care Medicine 2007;175:A127 [Abstract]

13. Gardner A, Smith B, Landry C. Differential temporal effects of the enantiomers of formoterol on cAMP signaling in human airway smooth muscle cells. American Journal of Respiratory and Critical Care Medicine 2007;175:A116 [Abstract]

14. Grogan DR, Hanrahan JP, Morganroth J, Cheng H, Baumgartner RA. Arrhythmias in COPD: Holter monitoring results from two arformoterol pivotal trials. American Journal of Respiratory and Critical Care Medicine 2007;175:A516 [Abstract]

15. Hanrahan JP, Calhoun WJ, Nelson H, Sciarappa K, McVicar WK, Baumgartner RA. An assessment of patient-centered outcomes following treatment with nebulized arformoterol in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2007;175:A618 [Abstract]

16. Scuirba F, Baumgartner RA, Sciarappa K, Benzo RP, Hanrahan JPH. Degree of exercise limitation in COPD: impact on 6-minute walk (6mw) in response to long-acting beta-agonist (LABA) treatment. European Respiratory Journal 2007;30(Suppl 51):76S [Abstract]

17. Baumgartner RA, Hanrahan J, Sciarappa K. Nebulized arformoterol, a long-acting ß2-adrenergic bronchodilator, in patients with COPD. Critical Care Medicine Dec. 2006;34(12 Suppl):A95 [Abstract]

18. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: A 12-week, multi-center, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clinical Therapeutics 2007; 29(2):261-278.

19. Bonasia P, Cook C, Cheng Y, Ong S. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. CMRO 2007;23(10):2477-2483.

20. Mhanna MJ, Koester JF, Cohn RC. Effects of (R,R)- and (R,R/S,S)-formoterol on airway relaxation and contraction in an experimental rat model. Current Therapeutic Research: Clinical and Experimental 2007;68(4):249-261.

21. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:502-506

22. Mahler DA, Criner GJ. Assessment tools for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:507-511.

23. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:512-521.

24. Agusti A. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:522-525.

25. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Bronchodilators. Proc Am Thorac Soc 2007;4:526-534.

26. Suissa S, McGhan, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:535-542.

27. Bailey WC, Tashkin DP. Pharmacologic therapy. Novel approaches for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:543-548.

28. ZuWallack R. The nonpharmacologic treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:549-553.

29. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564.

2006 BROVANA (arformoterol) Abstracts

1. Hanrahan J, Sciarappa K, Baumgartner RA. Nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. Critical Care Medicine Dec. 2006;(34):12:A95 (Abstract).

2. Zhou D, Huo M, Hsu SH, Hsu R, Maier G, Gu Z. Determination of (R,R)-formoterol and (S,S)-formoterol in human plasma using chiral liquid chromatography-tandem mass spectrometry. AAPS Journal 2006;8(S2):W4004 [Abstract].

3. Hanrahan JP, Sahn SA, Fogarty CM, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol in COPD: results from two prospective phase 3 clinical trials. Respiratory Care 2006;51(11):1321 [Abstract].

4. Donohue JF, Hanrahan JP, Grogan DR, Curry L, Sciarappa K, Baumgartner RA. Nebulized arformoterol in COPD: COPD exacerbations in elderly patients from two pooled phase 3 trials. Presented as a poster at American Society of Consultant Pharmacists annual meeting, November 15 - 18, 2006 in Phoenix, AZ. [Abstract].

5. Hanrahan JP, Sahn SA, Busse W, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. International Pharmaceutical Abstracts 2006 [Abstract].

6. Hanrahan JP, Sahn SA, Fogarty CM, Sciarappa K, Baumgartner Ra. Efficacy and safety of arformoterol in COPD: a prospective phase 3 clinical trial. Proceedings of the American Thoracic Society 2006;3:A847 [Abstract].

7. Baumgartner RA, Razzetti A, Claus R, McVicar W, Hanrahan JP. A crossover dose-ranging study of arformoterol in patients with COPD. Proceedings of the American Thoracic Society 2006;3:A847 [Abstract].

8. Hanrahan JP, Busse W, Smith WB, Sciarappa K, McVicar WK, Baumgartner RA. Efficacy and safety of nebulized arformoterol in COPD: A prospective phase 3 clinical trial. Chest 2006;130(4):181S [Abstract].

9. Hanrahan JP, Sahn S, Busse W, Sciarappa K, Baumgartner RA. Efficacy of nebulized arformoterol, a long-acting b2-adrenergic bronchodilator, in patients with COPD. European Respiratory Journal 2006;28(Suppl 50):215S [Abstract].

10. Hanrahan JP, Kerwin E, Cheng H, Grogan DR, Baumgartner Ra. Arformoterol in COPD: safety results from two pooled Phase 3 trials. European Respiratory Journal 2006;28(Suppl 50):428S [Abstract].

11. Maier G, Kharidia J, Hanrahan JP, Hsu R, Jaworowicz D, Cirincione B, Owen J, Grasela T. Exposure-response relationship for nebulized arformoterol in subjects with COPD. European Respiratory Journal 2006;28(Suppl 50):427S [Abstract].

12. Maier G, Kharidia J, Hanrahan JP, Hsu R, Jaworowicz D, Cirincione B, Owen J, Grasela T. Population pharmacokinetics of nebulized arformoterol in subjects with COPD. European Respiratory Journal 2006;28(Suppl 50):427S [Abstract].

13. Gu Z, Zhou D, Huo M, Hsu R, Hsu R, Maier G. Determination of in vivo chiral inversion of arformoterol to its diastereoisomers, (s,s)- formoterol, (r,s)- formoterol, and (s,r)- formoterol, by highly sensitive and specific LC/MS/MS methods in human plasma. Presented as a poster at the New England Drug Metabolism Discussion Group, June 8, 2006, Shrewsbury, MA [Abstract].

14. Barone LM, Ameredes BT, Calhoun WJ, Agrawal DK. The effect of the enantiomers of formoterol on inflammatory and constrictory properties in human airway smooth muscle cells. Presented as a poster at the North East Smooth Muscle Society annual meeting 2006, Boston, MA [Abstract].